(INNS)
ROMLUSEVIMAB(INNC)
IMMUNOGLOBULIN G1-LAMBDA2, ANTI-[SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN, RECEPTOR BINDING DOMAIN (RBD)], HOMO SAPIENS MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN HOMO SAPIENS (1-449) [VH (HOMO SAPIENS IGHV7-4-1*02 (95.9%) -(IGHD) -IGHJ6*01 (100%), CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -HOMO SAPIENS IGHG1*01, G1M17,1, G1V21 CH2 Y15.1, T16, E18 (CH1 K120 (216) (120-217), HINGE 1-15 (218-232), CH2 M15.1>Y (254), S16>T (256), T18>E (258) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)], (222-213')-DISULFIDE WITH LAMBDA2 LIGHT CHAIN HOMO SAPIENS (1'-214') [V-LAMBDA (HOMO SAPIENS IGLV3-21*01 (97.9%) -IGLJ2*01 (100%), CDR-IMGT [6.3.11] (26-31.49-51.88-98)) (1'-108') -HOMO SAPIENS IGLC2*01 (100%) (109'-214')]; DIMER (228-228'':231-231'')-BISDISULFIDE, PRODUCED IN A CHINESE HAMSTER OVARY (CHO)-K1 CELL LINE, GLYCOFORM ALFA(WHO)
ROMLUSEVIMABUM(INN)